JP2010539179A5 - - Google Patents

Info

Publication number

JP2010539179A5

JP2010539179A5 JP2010524973A JP2010524973A JP2010539179A5 JP 2010539179 A5 JP2010539179 A5 JP 2010539179A5 JP 2010524973 A JP2010524973 A JP 2010524973A JP 2010524973 A JP2010524973 A JP 2010524973A JP 2010539179 A5 JP2010539179 A5 JP 2010539179A5

Authority

JP

Japan

Prior art keywords

clostridium difficile

pharmaceutical composition

pharmaceutically acceptable

oritavancin

acceptable salt

Prior art date

2008-09-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 241000193163 Clostridioides difficile Species 0.000 claims description 19
• 239000008194 pharmaceutical composition Substances 0.000 claims description 13
• 239000000203 mixture Substances 0.000 claims description 9
• 150000003839 salts Chemical class 0.000 claims description 9
• 108010006945 oritavancin Proteins 0.000 claims description 8
• VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims description 8
• 229960001607 oritavancin Drugs 0.000 claims description 8
• 239000012453 solvate Substances 0.000 claims description 7
• 230000004913 activation Effects 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 239000003085 diluting agent Substances 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000035784 germination Effects 0.000 claims description 3
• 238000000338 in vitro Methods 0.000 claims description 3
• 238000001727 in vivo Methods 0.000 claims description 3
• 208000037384 Clostridium Infections Diseases 0.000 claims 6
• 206010009657 Clostridium difficile colitis Diseases 0.000 claims 6
• 206010054236 Clostridium difficile infection Diseases 0.000 claims 6
• 238000001990 intravenous administration Methods 0.000 claims 2
• 239000002904 solvent Substances 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 1
• 150000004677 hydrates Chemical class 0.000 claims 1
• 239000003910 polypeptide antibiotic agent Substances 0.000 description 9
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 9
• 230000002265 prevention Effects 0.000 description 6
• 238000000034 method Methods 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1